Clinical trial
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for…
NCT00388960 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00388960 |
|---|---|
| Title | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer |
| Official title | Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES) |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Amrubicin, Cisplatin, Etoposide |
| Enrollment | 99 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 17, 2006 |
| Last update posted | Nov 19, 2019 |
| Countries | Belgium, Italy, Netherlands, Poland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: